2021 has already been an exciting year for Clariness. We’ve supported enrollment for COVID-19 clinical trials and received funding from Europe’s Investment Fund for ClinLife, our patient-centric clinical trial database.
Want to know more about Clariness? Download our press kit below!
Clariness is doing its part to support and accelerate the world-wide release of a safe Covid-19 vaccine through its patient recruitment services for clinical trials
We’re experiencing increasing demand for patient recruitment services due to a growth of clinical trials conducted in China.
Strategic partnership between Parexel and CLARINESS to further accelerate clinical trial recruitment and patient engagement in China.
The President and Chairman of CLARINESS has been elected to the Advisory Board of the Center for Information and Study on Clinical Research Participation (CISCRP).
Over the last 13 years, CLARINESS has built a patient recruitment business covering 45 countries and 8 of the top 10 pharmaceutical companies. “Clinical trials face increasing challenges in terms of cost and timelines.”
CLARINESS is about bringing medical innovations to market faster by accelerating clinical trials.
Insightful remarks by Michael Stadler, Group CEO CLARINESS, in this article, published by European Investment Fund – Supporting entrepreneurship and innovation in Europe.
CLARINESS and a few other companies have been able in the short-term to order surgical masks, protective glasses and medical protective suits which we have donated to support China’s measures taken to contain the Corona epidemic.
How to ensure that patients know which trials are available and, more importantly, patients make a fully informed decision regarding participation? Read the current article at Medical Bag and learn some useful suggestions from our Head of Sales Operations, Dr. Henning Sievert.
(note: article is only available in German language)
The Viomedo portal attracted the interest of CLARINESS. With the acquisition the Swiss company wants to continue their growth.